Thoroughbred Financial Services LLC Makes New Investment in Zoetis Inc. (NYSE:ZTS)

Thoroughbred Financial Services LLC purchased a new position in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,737 shares of the company’s stock, valued at approximately $474,000.

Other large investors also recently modified their holdings of the company. Webster Bank N. A. increased its holdings in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Zoetis during the fourth quarter worth about $40,000. LRI Investments LLC bought a new position in shares of Zoetis during the first quarter worth about $43,000. Ables Iannone Moore & Associates Inc. bought a new position in shares of Zoetis during the fourth quarter worth about $51,000. Finally, Hazlett Burt & Watson Inc. grew its holdings in shares of Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after buying an additional 102 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Zoetis stock opened at $194.25 on Tuesday. The stock’s fifty day moving average price is $183.22 and its two-hundred day moving average price is $174.12. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a market cap of $88.00 billion, a PE ratio of 37.43, a price-to-earnings-growth ratio of 2.92 and a beta of 0.88.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter last year, the company earned $1.41 EPS. The company’s revenue was up 8.3% on a year-over-year basis. As a group, research analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ZTS shares. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a research report on Tuesday, August 27th. Finally, BTIG Research raised their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $217.11.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.